Helping the Mater Ovarian Cancer Research Collaborative (MOCRC) to take new ovarian cancer research discoveries from the laboratory to the patient’s bedside. Epithelial Ovarian Cancer (EOC) represents the fifth most common cause of female cancer death in Australia, with over 4,600 new cases recorded in 2010. Over the past decade, there has not been any significant progress in overall survival advantages with varying combinations of chemotherapy. There is a pressing need to establish novel treatments by developing EOC subtype specific clinical trials of combinations of therapies, with prior validation by laboratory and clinical research conducted by MOCRC.  Intended Results  (a) Molecular drivers of ovarian cancer (b) Targeted Delivery of Ovarian Cancer Antigens to Dendritic Cells for immunotherapy (c) Optimizing Therapeutic Antibodies for Ovarian Cancer.